Gut microbiome in non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) has a rapidly growing incidence worldwide, affecting approximately one-third of world population. The disturbance of gut commensal bacteria impacting host’s homeostasis is referred to as gut dysbiosis. The gut microbiome contributes to the pathogenesis of NA...

Full description

Saved in:
Bibliographic Details
Main Authors: Anastasios Mpountouridis, Christina Tsigalou, Ioanna Bezirtzoglou, Eugenia Bezirtzoglou, Elisavet Stavropoulou
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Gastroenterology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fgstr.2024.1534431/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841540096144179200
author Anastasios Mpountouridis
Christina Tsigalou
Ioanna Bezirtzoglou
Eugenia Bezirtzoglou
Elisavet Stavropoulou
author_facet Anastasios Mpountouridis
Christina Tsigalou
Ioanna Bezirtzoglou
Eugenia Bezirtzoglou
Elisavet Stavropoulou
author_sort Anastasios Mpountouridis
collection DOAJ
description Non-alcoholic fatty liver disease (NAFLD) has a rapidly growing incidence worldwide, affecting approximately one-third of world population. The disturbance of gut commensal bacteria impacting host’s homeostasis is referred to as gut dysbiosis. The gut microbiome contributes to the pathogenesis of NAFLD through various pathways. Gut microbiota is at constant interactions with the intestinal epithelial barrier and affects its integrity. Through gut-liver axis, gut microbiota may influence liver immune function. The release of lipopolysaccharides (LPS) from intestines to portal vein which are transported to the liver, may trigger hepatic inflammation, steatosis and even fibrosis. Moreover, the gut microbiome induces the conversion of primary bile acids (BAs) to secondary BAs, which activates intestinal receptors, such as FXR and TGR5. FXR activation decreases fat absorption and thus reduces hepatic lipid accumulation, while TGR5 activation promotes the release of glucagon-like peptide-1 (GLP-1) in blood. Furthermore, gut ethanol-producing bacteria has been implicated in NAFLD development. Additionally, in NAFLD there is a reduction in intestinal levels of short-chain fatty acids, such as butyrate, propionate and acetate. Many bacterial alterations have been observed in NAFLD, including the increased Bacteroidetes and decreased Firmicutes. Many probiotics have been tried in NAFLD prevention and management, including a plethora of strains from Lactobacilli, Bifidobacteria and Streptococcus and some of them have promising perspectives. There is also some promising data from the administration of prebiotics (such as inulin and fructo-oligosaccharides) and symbiotics (probiotics plus prebiotics). Faecal microbiota transplantation (FMT) is yet to be evaluated for its efficacy against NAFLD.
format Article
id doaj-art-28093c7d4ac44b3f982eb084f3f2782a
institution Kabale University
issn 2813-1169
language English
publishDate 2025-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Gastroenterology
spelling doaj-art-28093c7d4ac44b3f982eb084f3f2782a2025-01-14T06:10:35ZengFrontiers Media S.A.Frontiers in Gastroenterology2813-11692025-01-01310.3389/fgstr.2024.15344311534431Gut microbiome in non-alcoholic fatty liver diseaseAnastasios Mpountouridis0Christina Tsigalou1Ioanna Bezirtzoglou2Eugenia Bezirtzoglou3Elisavet Stavropoulou4Gastroenterology Department, Theagenio Cancer Hospital, Thessaloniki, GreeceLaboratory of Hygiene and Environmental Protection, Faculty of Medicine, Democritus University of Thrace, Alexandroupolis, GreeceSchool of Chemistry, University of Edinburgh, Scotland, United KingdomLaboratory of Hygiene and Environmental Protection, Faculty of Medicine, Democritus University of Thrace, Alexandroupolis, GreeceLaboratory of Hygiene and Environmental Protection, Faculty of Medicine, Democritus University of Thrace, Alexandroupolis, GreeceNon-alcoholic fatty liver disease (NAFLD) has a rapidly growing incidence worldwide, affecting approximately one-third of world population. The disturbance of gut commensal bacteria impacting host’s homeostasis is referred to as gut dysbiosis. The gut microbiome contributes to the pathogenesis of NAFLD through various pathways. Gut microbiota is at constant interactions with the intestinal epithelial barrier and affects its integrity. Through gut-liver axis, gut microbiota may influence liver immune function. The release of lipopolysaccharides (LPS) from intestines to portal vein which are transported to the liver, may trigger hepatic inflammation, steatosis and even fibrosis. Moreover, the gut microbiome induces the conversion of primary bile acids (BAs) to secondary BAs, which activates intestinal receptors, such as FXR and TGR5. FXR activation decreases fat absorption and thus reduces hepatic lipid accumulation, while TGR5 activation promotes the release of glucagon-like peptide-1 (GLP-1) in blood. Furthermore, gut ethanol-producing bacteria has been implicated in NAFLD development. Additionally, in NAFLD there is a reduction in intestinal levels of short-chain fatty acids, such as butyrate, propionate and acetate. Many bacterial alterations have been observed in NAFLD, including the increased Bacteroidetes and decreased Firmicutes. Many probiotics have been tried in NAFLD prevention and management, including a plethora of strains from Lactobacilli, Bifidobacteria and Streptococcus and some of them have promising perspectives. There is also some promising data from the administration of prebiotics (such as inulin and fructo-oligosaccharides) and symbiotics (probiotics plus prebiotics). Faecal microbiota transplantation (FMT) is yet to be evaluated for its efficacy against NAFLD.https://www.frontiersin.org/articles/10.3389/fgstr.2024.1534431/fullnon-alcoholic fatty liver disease (NAFLD)non-alcoholic steatohepatitis (NASH)gut microbiomegut microbiotagut dysbiosis
spellingShingle Anastasios Mpountouridis
Christina Tsigalou
Ioanna Bezirtzoglou
Eugenia Bezirtzoglou
Elisavet Stavropoulou
Gut microbiome in non-alcoholic fatty liver disease
Frontiers in Gastroenterology
non-alcoholic fatty liver disease (NAFLD)
non-alcoholic steatohepatitis (NASH)
gut microbiome
gut microbiota
gut dysbiosis
title Gut microbiome in non-alcoholic fatty liver disease
title_full Gut microbiome in non-alcoholic fatty liver disease
title_fullStr Gut microbiome in non-alcoholic fatty liver disease
title_full_unstemmed Gut microbiome in non-alcoholic fatty liver disease
title_short Gut microbiome in non-alcoholic fatty liver disease
title_sort gut microbiome in non alcoholic fatty liver disease
topic non-alcoholic fatty liver disease (NAFLD)
non-alcoholic steatohepatitis (NASH)
gut microbiome
gut microbiota
gut dysbiosis
url https://www.frontiersin.org/articles/10.3389/fgstr.2024.1534431/full
work_keys_str_mv AT anastasiosmpountouridis gutmicrobiomeinnonalcoholicfattyliverdisease
AT christinatsigalou gutmicrobiomeinnonalcoholicfattyliverdisease
AT ioannabezirtzoglou gutmicrobiomeinnonalcoholicfattyliverdisease
AT eugeniabezirtzoglou gutmicrobiomeinnonalcoholicfattyliverdisease
AT elisavetstavropoulou gutmicrobiomeinnonalcoholicfattyliverdisease